{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"79.6","upperLimit":"95.2","value":"87.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Standard Risk"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"75.7","upperLimit":"94.5","value":"85.1"},{"groupId":"OG001","lowerLimit":"75.0","upperLimit":"95.0","value":"85.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"60"}],"units":"Participants"}],"title":"High Risk"},{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"100","upperLimit":"100","value":"100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Induction Failure"}],"denoms":[{"counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"62"}],"units":"Participants"}],"description":"Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free.","dispersionType":"95% Confidence Interval","groups":[{"description":"No Nelarabine, Capizzi Methotrexate","id":"OG000","title":"ARM I (Combination Chemotherapy)"},{"description":"Nelarabine, Capizzi Methotrexate","id":"OG001","title":"ARM II (Combination Chemotherapy)"}],"paramType":"NUMBER","populationDescription":"Includes T-cell lymphoblastic lymphoma (T-LLy) patients that are standard risk, high risk and induction failures. All Standard risk T-LLy patients only received Arm I. Induction failures were assigned to Arm II.","reportingStatus":"POSTED","timeFrame":"4 years from end of induction","title":"Disease-free Survival (DFS) for T-cell Lymphoblastic Lymphoma (T-LLy) Cohort","type":"PRIMARY","unitOfMeasure":"percent probability"}